Compare JUBILANT LIFE SCIENCES with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES FRESENIUS KABI ONCO. JUBILANT LIFE SCIENCES/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 13.2 22.1 59.7% View Chart
P/BV x 1.7 3.1 53.1% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 JUBILANT LIFE SCIENCES   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
FRESENIUS KABI ONCO.
Mar-13
JUBILANT LIFE SCIENCES/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs898176 510.2%   
Low Rs61879 786.6%   
Sales per share (Unadj.) Rs572.037.7 1,517.8%  
Earnings per share (Unadj.) Rs36.25.1 711.3%  
Cash flow per share (Unadj.) Rs59.56.7 885.2%  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs301.942.5 709.6%  
Shares outstanding (eoy) m159.28158.23 100.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.4 39.2%   
Avg P/E ratio x20.925.0 83.7%  
P/CF ratio (eoy) x12.718.9 67.3%  
Price / Book Value ratio x2.53.0 83.9%  
Dividend payout %12.40-   
Avg Mkt Cap Rs m120,69420,135 599.4%   
No. of employees `0002.41.2 207.5%   
Total wages/salary Rs m19,260703 2,738.9%   
Avg. sales/employee Rs Th38,120.65,176.2 736.5%   
Avg. wages/employee Rs Th8,058.4610.4 1,320.1%   
Avg. net profit/employee Rs Th2,414.3699.6 345.1%   
INCOME DATA
Net Sales Rs m91,1085,963 1,527.9%  
Other income Rs m35718 1,985.6%   
Total revenues Rs m91,4665,981 1,529.3%   
Gross profit Rs m17,3901,430 1,216.0%  
Depreciation Rs m3,709258 1,438.2%   
Interest Rs m2,198-26 -8,454.2%   
Profit before tax Rs m11,8401,216 973.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,802-68 4,115.0%   
Tax Rs m3,268342 955.0%   
Profit after tax Rs m5,770806 716.0%  
Gross profit margin %19.124.0 79.6%  
Effective tax rate %27.628.1 98.1%   
Net profit margin %6.313.5 46.9%  
BALANCE SHEET DATA
Current assets Rs m45,8485,102 898.7%   
Current liabilities Rs m20,8972,385 876.1%   
Net working cap to sales %27.445.6 60.1%  
Current ratio x2.22.1 102.6%  
Inventory Days Days57150 37.9%  
Debtors Days Days51113 45.0%  
Net fixed assets Rs m65,4985,148 1,272.3%   
Share capital Rs m159158 100.7%   
"Free" reserves Rs m47,9306,556 731.1%   
Net worth Rs m48,0896,732 714.4%   
Long term debt Rs m42,429952 4,455.9%   
Total assets Rs m114,68510,388 1,104.0%  
Interest coverage x6.4-45.8 -14.0%   
Debt to equity ratio x0.90.1 623.8%  
Sales to assets ratio x0.80.6 138.4%   
Return on assets %6.97.5 92.5%  
Return on equity %12.012.0 100.2%  
Return on capital %12.414.6 85.0%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m12,4225,298 234.5%   
Fx outflow Rs m17,2271,772 972.1%   
Net fx Rs m-4,8053,525 -136.3%   
CASH FLOW
From Operations Rs m11,2151,274 880.2%  
From Investments Rs m-10,118-1,204 840.3%  
From Financial Activity Rs m6,574-196 -3,352.5%  
Net Cashflow Rs m7,612-126 -6,027.1%  

Share Holding

Indian Promoters % 45.6 0.0 -  
Foreign collaborators % 3.5 81.0 4.3%  
Indian inst/Mut Fund % 8.7 0.3 2,900.0%  
FIIs % 21.2 9.6 220.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 9.1 231.9%  
Shareholders   23,815 42,599 55.9%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 186 Points Higher; Energy and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day on a positive note.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Nov 19, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS